Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature.
Childs Nerv Syst
; 38(2): 465-472, 2022 02.
Article
de En
| MEDLINE
| ID: mdl-33948723
ABSTRACT
Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du cerveau
/
Tumeurs du cervelet
/
Médulloblastome
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
En
Journal:
Childs Nerv Syst
Sujet du journal:
NEUROLOGIA
/
PEDIATRIA
Année:
2022
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique